ClinicalTrials.gg

Program

F-2

Also written as “MK-4082”, “MK-4082 Formulation 2 (F2)” and “MK-4082 Formulation 4 (F4)”.

Its studies are led by Merck.

Furthest: phase 1, since Jan 29, 20263 company-led studies, 1 open or runningNext primary completion: Dec 15, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck31 open or runningphase 1since Jan 29, 2026Jan 29, 2026Dec 15, 2026phase 1 · NCT07748351

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2026First study: phase 1 study in HealthyFirst studyNCT07388667 · 122 enrolled · United States
  2. Jun 23, 2026Phase 1 study in HealthyNCT07697625 · 28 enrolled · United States
  3. Jul 31, 2026Phase 1 study in HealthyNCT07748351 · 48 enrolled · United States

Ahead

  1. Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07748351

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07748351Healthy · United States1Active, not recruitingDec 15, 202648
NCT07697625Healthy · United States1CompletedOct 6, 202628
NCT07388667Healthy · United States1CompletedSep 1, 2026122

How it is read

Names in the registry

  • “MK-4082”, 2 entries
  • “MK-4082 Formulation 2 (F2)”, 1 entry
  • “MK-4082 Formulation 4 (F4)”, 1 entry

Codes read as this program: MK4082.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.